Caroline Hamrick
Nurse Practitioner · Athens, GANPI 1225092398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $702 and has fallen 61.1% since, to $273 in 2025.
Across 82 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$212
- Johnson & Johnson$116
- Merck$105
- AstraZeneca$104
- Daiichi Sankyo Inc.$96
- Genentech USA, Inc.$84
- plus $961 from 27 others
What the payments were for
- Food & beverage$1,678100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $212 |
| Johnson & Johnson | 6 | $116 |
| Merck | 4 | $105 |
| AstraZeneca(2 entities) | 5 | $104 |
| Daiichi Sankyo Inc. | 5 | $96 |
| Genentech USA, Inc. | 4 | $84 |
| Sobi, Inc | 4 | $79 |
| Regeneron Healthcare Solutions, Inc. | 4 | $78 |
| Sanofi | 3 | $70 |
| Dilon Technologies, Inc. | 1 | $63 |
| Bayer | 3 | $59 |
| Seagen Inc. | 3 | $56 |
| Eisai Inc. | 3 | $54 |
| Boehringer Ingelheim | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Smith+Nephew | 2 | $33 |
| EMD Serono, Inc. | 2 | $32 |
| Exelixis Inc. | 2 | $32 |
| Karyopharm Therapeutics Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| ADC Therapeutics America, Inc. | 2 | $29 |
| Novartis | 1 | $26 |
| Taiho Oncology, Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Incyte Corporation | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Conmed Corporation | 1 | $17 |
| Beigene USA, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
How this compares
$1,678 in reported general payments places this provider in the 80th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 56 | $3,566 |
| Neomycin Sulfate | 27 | $152 |
| Metronidazole | 30 | $44 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Athens
- Sue PhelpsAthens$14K
- Andrea MealorAthens$10K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Tajuana BradleyJohns Creek$256K
- Jessica AdkinsSavannah$226K
- Janice McAlisterAtlanta$221K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.